Rozlytrek 200 mg hard capsules
Sponsors
F. Hoffmann-La Roche AG, Oslo University Hospital HF, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, HUS-Yhtymae
Conditions
Advanced CancerAdvanced solid tumorCancerLocally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3Multiple myelomaNon-Hodgkin lymphomaNon-small cell lung cancer with ROS proto-oncogene 1ROS1
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE II BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Active, not recruitingCTIS2023-505034-10-00
Start: 2016-08-01Target: 131Updated: 2025-09-03
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Active, not recruitingCTIS2023-507418-28-00
Start: 2021-03-15Target: 407Updated: 2025-12-09
Improving public cancer care by implementing precision medicine in Norway
A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway
RecruitingCTIS2023-507894-16-00
Start: 2021-04-01Target: 6000Updated: 2026-01-22
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile
Not yet recruitingCTIS2024-517478-68-01
Target: 250Updated: 2024-11-06
Phase 3
An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
RecruitingCTIS2023-504263-16-00
Start: 2023-05-25Target: 21Updated: 2025-11-05
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements with and Without Central Nervous System Metastases
RecruitingCTIS2023-507494-18-00
Start: 2021-09-24Target: 91Updated: 2026-01-20